Allogene Therapeutics Inc (NASDAQ: ALLO) has experienced a decline in its stock price by -1.25 compared to its previous closing price of 2.80. However, the company has seen a fall of -2.98% in its stock price over the last five trading days. gurufocus.com reported 2024-10-02 that Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The 36-month beta value for ALLO is also noteworthy at 0.83. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALLO is 138.03M, and at present, short sellers hold a 27.90% of that float. The average trading volume of ALLO on October 23, 2024 was 1.79M shares.
ALLO’s Market Performance
The stock of Allogene Therapeutics Inc (ALLO) has seen a -2.98% decrease in the past week, with a 3.56% rise in the past month, and a -4.98% fall in the past quarter. The volatility ratio for the week is 5.70%, and the volatility levels for the past 30 days are at 5.92% for ALLO. The simple moving average for the past 20 days is 1.93% for ALLO’s stock, with a -13.65% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at 3.40% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.12% of loss for the given period.
Volatility was left at 5.92%, however, over the last 30 days, the volatility rate increased by 5.70%, as shares surge +6.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.51% upper at present.
During the last 5 trading sessions, ALLO fell by -2.28%, which changed the moving average for the period of 200-days by -11.02% in comparison to the 20-day moving average, which settled at $2.71. In addition, Allogene Therapeutics Inc saw -13.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who proposed sale 36,404 shares at the price of $2.84 back on Oct 21 ’24. After this action, Parker Geoffrey M. now owns shares of Allogene Therapeutics Inc, valued at $103,501 using the latest closing price.
Douglas Earl Martin, the Officer of Allogene Therapeutics Inc, proposed sale 28,310 shares at $2.79 during a trade that took place back on Aug 21 ’24, which means that Douglas Earl Martin is holding shares at $78,844 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -3148.66 for the present operating margin
- -759.84 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -3237.8. The total capital return value is set at -0.44. Equity return is now at value -48.94, with -39.28 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -739.85.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 5894.95. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.25.
Conclusion
In summary, Allogene Therapeutics Inc (ALLO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
